文章：

B细胞成熟抗原在血液系统恶性肿瘤中的表达：一项系统性文献综述

B-cell maturation antigen expression across hematologic cancers: a systematic literature review

原文发布日期：2020-06-30

DOI: 10.1038/s41408-020-0337-y

类型: Review Article

开放获取: 是

英文摘要：

B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or therapeutic target in these diseases. Given advances in understanding the role of BCMA in B-cell development and the promise of BCMA as a therapeutic target, a systematic review is needed to rigorously assess the evidence for BCMA expression and identify areas of consensus and future research. The objective of this review was to summarize the evidence on BCMA protein and mRNA expression across hematologic malignancies. Using a PubMed database search up to 28 August 2019, a systematic literature review of publications reporting BCMA expression in patients with hematologic malignancies was conducted. Data from published congress abstracts presented at the American Society of Clinical Oncology and the American Society of Hematology were also searched. Studies that assessed BCMA expression (protein or mRNA) in patients of any age with hematologic malignancies were included. A total of 21 studies met inclusion criteria and were included in the review. BCMA was expressed in several hematologic malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma. BCMA was expressed at uniformly high levels across all 13 MM studies and at low to moderate levels in acute myeloid leukemia and acute lymphoblastic leukemia. These results suggest that BCMA is a relevant target in MM as well as in a subset of B-cell leukemia. BCMA expression in Hodgkin lymphoma and NHL varied across studies, and further research is needed to determine the utility of BCMA as an antibody target and biomarker in these diseases. Differences in sample type, timing of sample collection, and laboratory technique used may have affected the reporting of BCMA levels.
 

摘要翻译： 

B细胞成熟抗原（BCMA）在调节B细胞增殖和存活中起关键作用。现有证据表明BCMA在多种血液系统恶性肿瘤中存在表达，提示其可能作为生物标志物或治疗靶点在这些疾病中发挥重要作用。随着对BCMA在B细胞发育中作用认知的深入以及其作为治疗靶点的潜力显现，需要通过系统综述严格评估BCMA表达的证据，明确共识领域与未来研究方向。本综述旨在总结BCMA蛋白及mRNA在各类血液恶性肿瘤中表达的证据。通过检索截至2019年8月28日的PubMed数据库，对报道血液恶性肿瘤患者BCMA表达的文献进行系统综述，同时检索了美国临床肿瘤学会和美国血液学会发布的会议摘要数据。纳入所有评估任何年龄血液恶性肿瘤患者BCMA表达（蛋白或mRNA）的研究。共21项研究符合纳入标准。BCMA在多种血液恶性肿瘤中均有表达，包括多发性骨髓瘤（MM）、慢性淋巴细胞白血病、急性B淋巴细胞白血病、非霍奇金淋巴瘤（NHL）和霍奇金淋巴瘤。所有13项MM研究均显示BCMA呈持续高表达，而在急性髓系白血病和急性淋巴细胞白血病中呈低至中度表达。这些结果表明BCMA是MM及部分B细胞白血病的重要靶点。BCMA在霍奇金淋巴瘤和NHL中的表达在不同研究间存在差异，需进一步探索其作为抗体靶点和生物标志物在这些疾病中的应用价值。样本类型、采集时间及实验室技术的差异可能影响BCMA水平的报告结果。

原文链接：

B-cell maturation antigen expression across hematologic cancers: a systematic literature review